Suppr超能文献

晚期卵巢癌二次剖腹探查时的微观病变

Microscopic disease at second-look laparotomy in advanced ovarian cancer.

作者信息

Copeland L J, Gershenson D M, Wharton J T, Atkinson E N, Sneige N, Edwards C L, Rutledge F N

出版信息

Cancer. 1985 Jan 15;55(2):472-8. doi: 10.1002/1097-0142(19850115)55:2<472::aid-cncr2820550231>3.0.co;2-a.

Abstract

During the 11-year interval from January 1971 to January 1982, 50 of 246 patients with advanced (Stage III and IV) epithelial ovarian carcinoma at second-look laparotomy had biopsy or cytologic evidence of persistent microscopic carcinoma. The stage and grade profile include 46 Stage III and 4 Stage IV patients: 4 borderline, 9 grade 1, 20 grade 2 and 17 grade 3 patients. Following second-look laparotomy, 4 patients received no further therapy, 45 received chemotherapy, and 1 received external radiation. No patient was lost to follow-up, and the median interval off therapy was 24 months. Progressive or recurrent disease has manifest in 12 (24%). No recurrences have developed either in patients younger than age 40 or in patients with grade 1 tumors. Two patients died of leukemia, 1 died of heart disease, and 35 (70%) are alive with no evidence of disease. In patients developing recurrence, the median progression-free interval was 17.5 months, with a range of 6 to 46 months. The median interval of survival following disease progression was 7 months. There was no evidence of progression at 2 years and 5 years in 81% and 70% of patients, respectively. The uncorrected 2- and 5-year survival rates were 96% and 71%, respectively. The 5-year survival rates for grades 1, 2, and 3 were 100%, 79%, and 36%, respectively. Other variables analyzed include number of positive foci, residual tumor volume at initial surgery, cytologic findings at second-look laparotomy, type of chemotherapy, and number of courses of chemotherapy before second-look laparotomy. In summary, patients with only microscopic evidence of disease at second-look surgery have a good probability for extended survival.

摘要

在1971年1月至1982年1月的11年期间,246例接受二次剖腹探查术的晚期(Ⅲ期和Ⅳ期)上皮性卵巢癌患者中,有50例经活检或细胞学检查证实存在持续性微小癌。分期和分级情况包括46例Ⅲ期和4例Ⅳ期患者:4例为交界性,9例为1级,20例为2级,17例为3级。二次剖腹探查术后,4例患者未接受进一步治疗,45例接受了化疗,1例接受了外照射。无患者失访,停止治疗的中位间隔时间为24个月。12例(24%)出现了疾病进展或复发。年龄小于40岁的患者或1级肿瘤患者均未出现复发。2例患者死于白血病,1例死于心脏病,35例(70%)存活且无疾病证据。在出现复发的患者中,无进展生存期的中位时间为17.5个月,范围为6至46个月。疾病进展后的中位生存时间为7个月。分别有81%和70%的患者在2年和5年时无进展证据。未经校正的2年和5年生存率分别为96%和71%。1级、2级和3级的5年生存率分别为100%、79%和36%。分析的其他变量包括阳性病灶数量、初次手术时的残留肿瘤体积、二次剖腹探查术时的细胞学检查结果、化疗类型以及二次剖腹探查术前的化疗疗程数。总之,二次剖腹探查手术时仅存在微小疾病证据的患者有延长生存期的良好可能性。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验